[TENAGA] QoQ Cumulative Quarter Result on 30-Sep-2022 [#3]

Announcement Date
23-Nov-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Sep-2022 [#3]
Profit Trend
QoQ- 50.35%
YoY- -4.66%
Quarter Report
View:
Show?
Cumulative Result
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Revenue 25,948,800 12,625,600 50,867,700 53,872,200 34,798,800 15,658,500 52,629,500 -37.67%
PBT 1,644,200 1,102,700 5,348,600 4,531,900 2,997,700 1,532,000 4,738,300 -50.71%
Tax -442,400 -171,800 -1,791,200 -1,782,400 -1,220,900 -660,800 -873,600 -36.54%
NP 1,201,800 930,900 3,557,400 2,749,500 1,776,800 871,200 3,864,700 -54.19%
-
NP to SH 1,330,200 1,002,300 3,463,300 2,654,200 1,765,300 893,100 3,661,800 -49.18%
-
Tax Rate 26.91% 15.58% 33.49% 39.33% 40.73% 43.13% 18.44% -
Total Cost 24,747,000 11,694,700 47,310,300 51,122,700 33,022,000 14,787,300 48,764,800 -36.45%
-
Net Worth 57,994,981 57,847,770 58,367,948 57,290,902 58,107,800 56,581,226 56,523,361 1.73%
Dividend
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Div 1,036,097 - 2,639,681 1,146,701 1,145,218 - 2,287,006 -41.09%
Div Payout % 77.89% - 76.22% 43.20% 64.87% - 62.46% -
Equity
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Net Worth 57,994,981 57,847,770 58,367,948 57,290,902 58,107,800 56,581,226 56,523,361 1.73%
NOSH 5,787,331 5,753,077 5,753,077 5,753,077 5,726,091 5,726,091 5,726,091 0.71%
Ratio Analysis
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
NP Margin 4.63% 7.37% 6.99% 5.10% 5.11% 5.56% 7.34% -
ROE 2.29% 1.73% 5.93% 4.63% 3.04% 1.58% 6.48% -
Per Share
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 450.81 219.46 886.44 939.60 607.72 273.46 920.50 -37.94%
EPS 23.11 17.42 60.35 46.29 30.83 15.60 64.05 -49.41%
DPS 18.00 0.00 46.00 20.00 20.00 0.00 40.00 -41.36%
NAPS 10.0754 10.0551 10.1714 9.9923 10.1479 9.8813 9.886 1.27%
Adjusted Per Share Value based on latest NOSH - 5,753,077
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 446.40 217.20 875.08 926.76 598.64 269.37 905.38 -37.66%
EPS 22.88 17.24 59.58 45.66 30.37 15.36 62.99 -49.18%
DPS 17.82 0.00 45.41 19.73 19.70 0.00 39.34 -41.10%
NAPS 9.9769 9.9515 10.041 9.8557 9.9963 9.7337 9.7237 1.73%
Price Multiplier on Financial Quarter End Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 -
Price 9.05 9.23 9.63 8.05 7.98 9.00 9.34 -
P/RPS 2.01 4.21 1.09 0.86 1.31 3.29 1.01 58.41%
P/EPS 39.16 52.98 15.96 17.39 25.88 57.70 14.58 93.57%
EY 2.55 1.89 6.27 5.75 3.86 1.73 6.86 -48.39%
DY 1.99 0.00 4.78 2.48 2.51 0.00 4.28 -40.06%
P/NAPS 0.90 0.92 0.95 0.81 0.79 0.91 0.94 -2.86%
Price Multiplier on Announcement Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 25/08/23 29/05/23 27/02/23 23/11/22 30/08/22 30/05/22 24/02/22 -
Price 9.97 9.75 9.64 8.42 8.99 9.25 9.00 -
P/RPS 2.21 4.44 1.09 0.90 1.48 3.38 0.98 72.22%
P/EPS 43.14 55.96 15.97 18.19 29.16 59.31 14.05 111.68%
EY 2.32 1.79 6.26 5.50 3.43 1.69 7.12 -52.74%
DY 1.81 0.00 4.77 2.38 2.22 0.00 4.44 -45.11%
P/NAPS 0.99 0.97 0.95 0.84 0.89 0.94 0.91 5.79%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment